Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucie Ellis-Taitt

Managing Editor, In Vivo

London, UK
Prior to leading In Vivo, Lucie was a senior editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo online as well as the annual Outlook publication. Covering the biopharma space since 2012, Lucie writes feature articles on the topics of leadership, R&D, innovation and more. She also regularly attends industry events and moderates panel discussions on topics such as investment trends, women’s health and R&D hot topics.

Latest From Lucie Ellis-Taitt

‘Pharma Is Not Just A Cost Component’ – Showcasing Value As Well As Innovation

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.

Market Access C-Suite Speaks

AI-Driven CHARM’s Number One Goal: Transitioning To A Clinical-Stage Biotech

Laksh Aithani, CEO of CHARM Therapeutics, discusses key challenges for the flourishing AI drug development sector including finding the right people and the need for more success stories.

Rising Leaders Clinical Trials

Rezo’s Platform Could ‘Fundamentally Shift’ Drug Discovery

Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.

New Science C-Suite Speaks

Apogee CMO On New Approach To I&I Market

Having raised $345m in an IPO last year, prior to entering the clinic, Apogee Therapeutics has emerged as a startup to watch. Chief medical officer Carl Dambkowski, one of In Vivo’s 2024 Rising Leaders, shares more about the biotech’s pipeline strategy.

Inflammation Rising Leaders

Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline

Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.

Rising Leaders Oncology

Six New Molecules By 2030 – J&J’s Neuroscience Strategy

Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions. 

Neurology Research & Development
See All